Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
Completed · Phase 2
Conditions studied: Male Breast Cancer, Recurrent Breast Cancer, Skin Metastases, Stage IV Breast Cancer
In brief
This phase II trial is studying the side effects of giving topical imiquimod together with Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) to see how well it works in treating patients with advanced breast cancer. Biological therapies, such as imiquimod, may stimulate the immune system to kill tumor cells. Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imiquimod together with Abraxane may kill more tumor cells.
Key facts
- Study ID
- NCT00821964
- Run by
- University of Washington
- People needed
- 15
- Starts
- 2008-12-01
- Expected to finish
- 2012-11-29
- Last updated by the study team
- 2018-01-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with advanced stage refractory breast cancer
- Progressive or relapsed disease following standard therapy with chemotherapy and/or surgery, and/or radiation
- Patients must have measurable (bi-dimensional) chest wall disease and/or cutaneous metastatic lesions
- Patients must be at least 7 days from last chemotherapy and 30 days from local radiotherapy and/or systemic steroids
- Patients on bisphosphonates, trastuzumab, lapatinib and/or hormonal therapy are eligible
- White blood cell count >= 1000/ul
- Absolute neutrophil count (ANC) >= 1200/ul
- Platelets > 75,000/ul
- Serum creatinine =< 2.0 mg/dL, a creatinine clearance > 60 ml/min
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2 X upper limit normal (ULN)
- Total bilirubin < 2 X ULN
- Patients must have a Performance Status Score (Eastern Cooperative Oncology Group [ECOG] Scale) =< 2
- Patients must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have a significant active concurrent medical illness precluding protocol treatment
- Men and women of reproductive ability must agree to contraceptive use during the study and for 1 month after imiquimod/Abraxane treatment is discontinued
You may not qualify if…
- Patients with prior allergic reaction to taxanes
- Patients with any clinically significant active autoimmune disease requiring active treatment with systemic steroids or other immunomodulators
- Pregnant or breast-feeding women
- Patients with peripheral neuropathy >= Grade 2
Where it is running
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.